Gilead Sciences (NASDAQ:GILD) Issues FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.650–0.300 for the period, compared to the consensus earnings per share estimate of -0.790. The company issued revenue guidance of $30.1 billion-$30.4 billion, compared to the consensus revenue estimate of $30.5 billion.

Gilead Sciences Trading Down 1.4%

Shares of NASDAQ GILD traded down $1.86 during mid-day trading on Thursday, reaching $129.90. 2,187,887 shares of the company’s stock were exchanged, compared to its average volume of 7,144,190. The company’s 50-day moving average is $129.54 and its 200-day moving average is $136.18. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market capitalization of $161.28 billion, a price-to-earnings ratio of -48.68 and a beta of 0.32. Gilead Sciences has a 52-week low of $108.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 1.86% and a negative net margin of 10.64%.The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.01 earnings per share. Analysts expect that Gilead Sciences will post -0.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GILD. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Royal Bank Of Canada increased their price target on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday. Finally, Rothschild & Co Redburn cut their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,000 shares of company stock worth $10,641,790 over the last ninety days. 0.30% of the stock is owned by company insiders.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s second-quarter revenue rose 10.6% year over year to $7.8 billion, exceeding analysts’ $7.4 billion estimate. The company reported a loss of $6.75 per share, but that was narrower than expectations of roughly $7.07–$7.26. Gilead Q2 Results
• Positive Sentiment: HIV remained the company’s primary growth driver. Product sales excluding Veklury increased 10% to $7.6 billion, while PrEP sales reportedly doubled to approximately $1 billion, supported by the launch and early uptake of Yeztugo. Management raised its full-year HIV growth outlook to 9%–10% and projected 2026 base-business sales of $29.8 billion–$30.1 billion. Gilead Raises HIV Outlook
• Positive Sentiment: Analyst sentiment remains broadly supportive. Cantor Fitzgerald reaffirmed an Overweight rating with a $155 price target, while Needham reiterated Buy with a $170 target. Analyst Ratings
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and an indicated yield of about 2.5%. The payout supports shareholder returns, although it is unlikely to materially change the near-term trading outlook.
• Negative Sentiment: Gilead and MSD discontinued a Phase III study combining Trodelvy with Keytruda after lackluster interim data. The failure is a setback for efforts to expand Trodelvy in combination and monotherapy settings and may increase concern about the oncology pipeline. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Acquisition-related charges and elevated research spending pushed Gilead into a substantial quarterly loss and deepened projected full-year losses, overshadowing the operating beat. Veklury sales also fell 81%, prompting a reduction in its annual outlook. Gilead Second-Quarter Sales
• Negative Sentiment: AIDS Healthcare Foundation criticized Gilead’s HIV pricing and licensing policies in lower-income countries, creating potential reputational and access-related risks. HIV Drug Access Criticism

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Amundi raised its position in Gilead Sciences by 25.5% in the 4th quarter. Amundi now owns 9,520,135 shares of the biopharmaceutical company’s stock valued at $1,168,501,000 after purchasing an additional 1,936,354 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares during the last quarter. Bank of Nova Scotia boosted its stake in Gilead Sciences by 371.4% in the fourth quarter. Bank of Nova Scotia now owns 1,227,279 shares of the biopharmaceutical company’s stock worth $150,636,000 after purchasing an additional 966,905 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in shares of Gilead Sciences by 50.6% during the fourth quarter. Raymond James Financial Inc. now owns 2,734,917 shares of the biopharmaceutical company’s stock worth $336,007,000 after purchasing an additional 919,106 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.